This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Myotonic dystrophy (Steinert disease)Myotonic Dystrophy (Steinert Disease / DM1 / DM2)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: G71.1 | Special Copayment Reduction: V012 | Registration validity period: 5 years
B. SynonymsMyotonic dystrophy [Steinert], myotonic muscular dystrophy, Dystrophia Myotonica, DM1, DM2
C. Adult onsetLikelihood of first onset in adulthood: high — Adult-type DM1 first presents mainly in the 20s–30s, and DM2 usually presents in the 30s–50s.
1. HistoryGo to section
2. CausesGo to section
3. GeneticsGo to section
4. General epidemiologyGo to section
5. PathophysiologyGo to section
6. SymptomsGo to section
7. SignsGo to section
8. ScreeningGo to section
9. DiagnosisGo to section
10. TreatmentGo to section
11. PrognosisGo to section
12. PreventionGo to section
13. ReferencesGo to section

1. History

The clinical description of myotonic dystrophy was first reported independently in 1909 by Hans Gustav Wilhelm Steinert of Germany and by Frederick Batten and Herbert Gibb of the United Kingdom. Steinert systematically described a clinical syndrome in which myotonia and muscular atrophy coexist, and it later came to be called 'Steinert disease' after him. Until the mid-20th century, classification based on the clinical phenotype predominated. In 1936, Caughey and Myrianthopoulos published a systematic clinical description, and it was gradually revealed to be a multiorgan disease including ophthalmic, cardiac, and endocrine involvement. In 1992, Brook et al. first identified an abnormal expansion of a CTG trinucleotide repeat sequence in the 3'UTR region of the DMPK gene on the long arm of chromosome 19 as the cause of DM1. This became the starting point of a new pathogenic concept, RNA toxicity due to repeat expansion. Subsequently, in 2001, Liquori et al. identified a CCTG repeat expansion within intron 1 of the CNBP gene on chromosome 3 as the cause of myotonic dystrophy type 2 (DM2). DM2 was confirmed to be the same disease as the clinical group formerly called proximal myotonic myopathy (PROMM, Proximal Myotonic Myopathy) or Ricker disease. Since the 2000s, the mechanism of aberrant splicing through sequestration of MBNL (Muscleblind-like) proteins and hyperactivation of CELF (CUGBP/Elav-like family) proteins has been studied in depth, establishing the current pathogenic model.

2. Causes

Myotonic dystrophy is an autosomal dominant genetic disease caused by abnormal expansion (dynamic mutation) of trinucleotide or tetranucleotide repeat sequences within the noncoding regions of two independent genes.

In both types, the core of pathogenesis is an RNA toxicity mechanism in which transcripts containing the abnormal repeat sequences (CUG or CCUG repeat RNA) accumulate in the nucleus and interact abnormally with specific RNA-binding proteins, causing aberrant splicing. Reduction of the DMPK protein itself (haploinsufficiency) and suppressed expression of adjacent genes (SIX5, etc.) are also known to contribute to some phenotypes.

3. Genetics

Both DM1 and DM2 follow an autosomal dominant mode of inheritance. Genetic anticipation, in which the repeat number expands further when transmitted from a parent carrying the mutation to a child, is prominent. In DM1 in particular, maternal transmission tends to result in congenital myotonic dystrophy (CDM), which is associated with very large CTG expansions of hundreds to thousands of repeats.

DM1 shows somatic mosaicism, with repeat numbers differing between tissues. The repeat number in leukocytes is smaller than in skeletal or cardiac muscle, so clinical severity may be underestimated. In DM2, the range of repeat number variation is very wide (up to about 11,000 CCTG), genetic anticipation is less pronounced than in DM1, and no congenital form has been reported.

CharacteristicsDM1DM2
Causative geneDMPK (19q13.32)CNBP (3q21.3)
Location of repeat sequenceCTG (3'UTR)CCTG (intron 1)
Normal repeat number5–37 repeats<26 repeats
Pathological repeat number≥50 repeats (premutation: 38–49)75–11,000 repeats
Genetic anticipationProminent (especially maternal)Relatively mild
Occurrence of congenital formYes (with maternal transmission)Not reported
Distribution of main muscles involvedDistal predominanceProximal predominance

4. General epidemiology

Myotonic dystrophy is the most common hereditary muscle disease in adults. The worldwide prevalence of DM1 is estimated at about 1/8,000–1/20,000, with wide regional variation. In the Saguenay-Lac-Saint-Jean region of Quebec, Canada, the prevalence is reported to reach about 1/550 due to a founder effect. In contrast, prevalence is relatively low in some regions of Asia and Africa.

The prevalence of DM2 is known to be lower than that of DM1, but because symptoms are mild and diagnosis is difficult, it is likely to be underdiagnosed in reality. Some European countries such as Germany and Finland have reported a DM2 prevalence similar to or higher than that of DM1. In Korea, accurate epidemiological data are limited, but according to rare disease registry data, myotonic dystrophy accounts for a considerable proportion of congenital muscle diseases. Incidence is equal in men and women without sex differences, but in the clinical phenotype, frontal balding and male infertility are prominent in men, and pregnancy complications (abnormal uterine contractions, prolonged labor, fetal abnormalities) are important clinical problems in women.

5. Pathophysiology

The pathogenesis of myotonic dystrophy is explained by a 'gain-of-function RNA toxicity' mechanism. CUG repeat RNA transcribed from the mutant allele of the DMPK gene (DM1) or CCUG repeat RNA transcribed from the CNBP gene (DM2) forms aggregates (nuclear foci) within the cell nucleus.

These abnormal RNA aggregates sequester the RNA-binding protein MBNL1 (Muscleblind-like 1), causing loss of its normal splicing regulatory function. At the same time, the CELF1 (CUGBP Elav-like family member 1) protein is hyperactivated through phosphorylation. These two changes abnormally shift the splicing of many pre-mRNAs to fetal isoforms, leading to dysfunction in multiple tissues.

6. Symptoms

Myotonic dystrophy is a multisystem disease; in addition to musculoskeletal symptoms, various organs such as the heart, eyes, endocrine system, and central nervous system are involved.

Musculoskeletal system

Cardiac

Eye

Endocrine and metabolic

Central nervous system

Gastrointestinal

7. Signs

Myotonia-related signs

Signs related to weakness and muscle atrophy

Cardiac signs

Ophthalmic signs

Laboratory findings

8. Screening

Screening is performed when there is a family history (autosomal dominant inheritance, early cataracts, cardiac conduction disorders, myotonic symptoms) or when a characteristic clinical phenotype is observed.

9. Diagnosis

Diagnosis is confirmed by molecular genetic testing demonstrating a repeat expansion in the DMPK or CNBP gene.

Molecular genetic testing

Ancillary diagnostic tests

Differential diagnosis

10. Treatment

There is currently no curative treatment; multidisciplinary symptomatic treatment and prevention of complications are the core of management.

Relief of myotonia

Cardiac management

Respiratory management

Ophthalmologic and other organ management

Rehabilitation and physical therapy

Treatment of hypersomnia

New drug development

11. Prognosis

The prognosis of myotonic dystrophy varies greatly with disease type, age of onset, repeat size, and pattern of organ involvement. Adult-onset DM1 follows a progressive course, with gradual progression of muscle weakness and decline in respiratory function. The main causes of death are respiratory failure and sudden death from cardiac arrhythmia. According to large cohort studies, the mean age at death of patients with DM1 is significantly lower than in the general population, and cardiac-related deaths account for about 30% of all causes of death. Congenital DM1 has high perinatal mortality, and survivors often have severe intellectual disability. DM2 generally follows a milder course than adult-onset DM1, and shortening of life expectancy may be less than in DM1. However, cardiac complications also occur in DM2, so regular cardiac surveillance is essential. Systematic multidisciplinary follow-up (neurology, cardiology, pulmonology, ophthalmology, endocrinology, rehabilitation medicine) contributes to preventing complications and improving survival.

12. Prevention

Because myotonic dystrophy is a genetic disease, primary prevention is achieved through genetic counseling and preconception genetic diagnosis.

13. References

  1. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992;68(4):799–808. PMID: 1310900
  2. Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293(5531):864–867. PMID: 11486088
  3. Thornton CA. Myotonic dystrophy. Neurol Clin. 2014;32(3):705–719. DOI: 10.1016/j.ncl.2014.04.011
  4. Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. J Neurol Neurosurg Psychiatry. 2010;81(4):358–367. PMID: 20176601
  5. Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol. 2012;11(10):891–905. PMID: 22995693
  6. Meola G, Cardani R. Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms. Biochim Biophys Acta. 2015;1852(4):594–606. PMID: 25159707
  7. Wahbi K, Babuty D, Probst V, et al. Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. Eur Heart J. 2017;38(10):751–758. PMID: 27371720
  8. Logigian EL, Martens WB, Moxley RT 4th, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology. 2010;74(18):1441–1448. PMID: 20439846
  9. Heatwole C, Luebbe E, Rosero S, et al. Mexiletine in myotonic dystrophy type 1: a randomized, double-blind, placebo-controlled trial. Neurology. 2021;96(2):e228–e238. PMID: 33208506
  10. Overby SJ, Cerro-Herreros E, Llamusi B, Artero R. RNA-mediated therapies in myotonic dystrophy. Drug Discov Today. 2018;23(12):2013–2022. PMID: 30267771